GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmosa Biopharm Inc (ROCO:6875) » Definitions » Enterprise Value

Pharmosa Biopharm (ROCO:6875) Enterprise Value : NT$7,776.1 Mil (As of Jun. 06, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Pharmosa Biopharm Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Pharmosa Biopharm's Enterprise Value is NT$7,776.1 Mil. Pharmosa Biopharm's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was NT$22.5 Mil. Therefore, Pharmosa Biopharm's EV-to-EBIT ratio for today is 346.10.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Pharmosa Biopharm's Enterprise Value is NT$7,776.1 Mil. Pharmosa Biopharm's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was NT$48.2 Mil. Therefore, Pharmosa Biopharm's EV-to-EBITDA ratio for today is 161.40.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Pharmosa Biopharm's Enterprise Value is NT$7,776.1 Mil. Pharmosa Biopharm's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was NT$314.6 Mil. Therefore, Pharmosa Biopharm's EV-to-Revenue ratio for today is 24.72.


Pharmosa Biopharm Enterprise Value Historical Data

The historical data trend for Pharmosa Biopharm's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmosa Biopharm Enterprise Value Chart

Pharmosa Biopharm Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial - - - 6,392.99 9,484.26

Pharmosa Biopharm Quarterly Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,074.40 12,638.10 9,376.88 9,484.26 8,588.90

Competitive Comparison of Pharmosa Biopharm's Enterprise Value

For the Biotechnology subindustry, Pharmosa Biopharm's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmosa Biopharm's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmosa Biopharm's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Pharmosa Biopharm's Enterprise Value falls into.



Pharmosa Biopharm Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Pharmosa Biopharm's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Pharmosa Biopharm's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmosa Biopharm  (ROCO:6875) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Pharmosa Biopharm's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=7776.084/22.468
=346.10

Pharmosa Biopharm's current Enterprise Value is NT$7,776.1 Mil.
Pharmosa Biopharm's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$22.5 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Pharmosa Biopharm's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=7776.084/48.179
=161.40

Pharmosa Biopharm's current Enterprise Value is NT$7,776.1 Mil.
Pharmosa Biopharm's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$48.2 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Pharmosa Biopharm's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=7776.084/314.575
=24.72

Pharmosa Biopharm's current Enterprise Value is NT$7,776.1 Mil.
Pharmosa Biopharm's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$314.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmosa Biopharm Enterprise Value Related Terms

Thank you for viewing the detailed overview of Pharmosa Biopharm's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmosa Biopharm (ROCO:6875) Business Description

Traded in Other Exchanges
N/A
Address
No.66, Sanchong Road, Nangang District, Taipei, TWN, 11502
Pharmosa Biopharm Inc is a world-class biotechnology company focusing on developing a new drug by exploiting proprietary formulation and manufacturing technology.

Pharmosa Biopharm (ROCO:6875) Headlines

No Headlines